BWM
AMAM

BerganKDV Wealth Management’s Ambrx Biopharma Inc AMAM Stock Holding History

BerganKDV Wealth Management’s Portfolio AMAM Stock Details AMAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$1.65K Hold
100
– – ﹤0.01% 707
2023
Q1 		$892 Buy
+100
New +$503 ﹤0.01% 915

Other funds holding AMAM

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

BerganKDV Wealth Management's AMAM Position: Q2 2023 in Review

BerganKDV Wealth Management held its Ambrx Biopharma Inc (AMAM) position steady in Q2 2023 at 100 shares worth $1.65K. The position accounts for ﹤0.01% of the portfolio, ranked #707.

BerganKDV Wealth Management first reported a position in AMAM in Q1 2023 and has held it in 2 quarters since. 42 funds tracked by Wall St. Rank hold AMAM as of Q2 2023.

  • BerganKDV Wealth Management held 100 shares of Ambrx Biopharma Inc worth $1.65K as of Q2 2023.
  • BerganKDV Wealth Management left its Ambrx Biopharma Inc share count unchanged in Q2 2023.
  • Ambrx Biopharma Inc made up ﹤0.01% of BerganKDV Wealth Management's portfolio in Q2 2023, its #707 holding.
  • BerganKDV Wealth Management first reported a position in Ambrx Biopharma Inc in Q1 2023 and has held it in 2 quarters since.
  • 42 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q2 2023.

Based on BerganKDV Wealth Management's 13F filing for Q2 2023, filed 24 Jul 2023.